Xenetic Biosciences, Inc. (XBIO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenetic Biosciences, Inc. on December 1, 2022. The Company is incorporated in Nevada and maintains its principal executive offices in Framingham, Massachusetts. Its common stock and purchase warrants trade on The Nasdaq Stock Market under the symbols "XBIO" and "XBIOW," respectively.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance regarding stock listing status rather than financial performance.
Material Changes and Listing Status
The primary event reported is the Company's continued non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding the minimum bid price requirement of $1.00 per share. On June 3, 2022, the Company was notified that its stock had traded below $1.00 for 30 consecutive business days. On December 1, 2022, Nasdaq granted the Company an additional 180-day compliance period, extending until May 29, 2023.
To regain compliance, the Company must meet the following criteria:
- The closing bid price must reach or exceed $1.00 per share for a minimum of 10 consecutive business days (subject to Nasdaq discretion).
- The Company has indicated its intention to cure the deficiency by effecting a reverse stock split if necessary.
- The Company has met all other applicable requirements for initial listing, including the market value of publicly held shares.
Outlook, Risks, and Contingencies
Management stated it will continue to monitor the closing bid price and consider available options to resolve the deficiency. The filing explicitly states there can be no assurance that the Company will regain compliance within the allotted period. If the Company fails to comply by May 29, 2023, Nasdaq will provide notice that the common stock will be subject to delisting. The Company retains the right to appeal such a determination to a Nasdaq hearings panel.
Key Facts for Investor Verification
- Compliance Deadline: The Company has until May 29, 2023, to regain compliance with the $1.00 minimum bid price requirement.
- Delisting Risk: Failure to meet the bid price requirement by the deadline will result in a notice of delisting.
- Proposed Remedy: The Company intends to effect a reverse stock split if the market price does not naturally recover.
- Current Status: As of the filing date, the stock price remained below the $1.00 threshold.